AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion clinical trials

Phase Ib/II trial of the combination of atezolizumab with dendritic cell vaccination as maintenance treatment in patients with extensive stage small cell lung cancer (ES-SCLC) after induction treatment.

This study is looking at a new way to treat extensive small cell lung cancer. It combines a drug called atezolizumab with a special vaccine made from your own cells. The aim is to see if this combination can help people live longer without their cancer growing after initial treatment.